




RealRate

PHARMACEUTICAL 2019

RELMADA THERAPEUTICS INC.
Rank 328 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

RELMADA THERAPEUTICS INC. Rank 328 of 371

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 232% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 292% points.

The company's Economic Capital Ratio, given in the ranking table, is -731%, being 400% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	2,738
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,905
Liabilities, Non-Current	0
Other Assets	298
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,656
Other Net Income	-2,043
Property and Equipment	12
Research and Development	2,943
Revenues	0
Selling, General and Administrative Expense	3,975

Output Variable	Value in 1000 USD
Assets	3,048
Liabilities	8,561
Expenses	6,917
Stockholders Equity	-5,513
Net Income	-8,961
Comprehensive Net Income	-8,961
Economic Capital Ratio	-731%

